UPDATE: FDA approves another Humira biosimilar

27 August 2017
biosimilars_samples_large

The US Food and Drug Administration on Friday approved Cyltezo (adalimumab-adbm) for multiple indications as a biosimilar of AbbVie’s (NYSE: ABBV) Humira.

Adalimumab-adbm Cyltezo, from German family-owned pharma major Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.

This is the second FDA-approved biosimilar to US-licensed Humira, following Amgen’s (Nasdaq: AMGN) Amjevita (adalimumab-atto), which was cleared for marketing in September 2016. And, just last week, Samsung Bioepis gained European Commission approval for its Imraldi biosimilar of Humira. In March this year, Amgen also gained European approval for its biosimilar under the brand name Amgevita in March this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars